NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 11/03/2025 at 14:35, 5 months 28 days ago

NanoViricides to Present at Spartan Capital Investor Conference 2025

NanoViricides NV-387 Clinical Trials Antiviral Drugs Spartan Capital Conference
PRESS RELEASE

published on 11/03/2025 at 14:30, 5 months 28 days ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing

NanoViricides NV-387 Clinical Trial Antiviral Drug Spartan Capital Investor Conference
BRIEF

published on 10/29/2025 at 13:50, 6 months 3 days ago

NV-387: A Promising Antiviral Agent for Measles

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Treatment
PRESS RELEASE

published on 10/29/2025 at 13:45, 6 months 3 days ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus
BRIEF

published on 10/27/2025 at 13:50, 6 months 5 days ago

NanoViricides Set to Present at PODD 2025 Conference

NanoViricides NV-387 Biotechnology Clinical Trials Antiviral Drug
PRESS RELEASE

published on 10/27/2025 at 13:45, 6 months 5 days ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
NanoViricides, Inc. to present at PODD 2025 Conference with focus on revolutionary broad-spectrum antiviral drugs in development for various viral infections

Respiratory Viral Infections NV-387 Antiviral Drugs NanoViricides, Inc. PODD 2025 Conference
BRIEF

published on 10/22/2025 at 14:50, 6 months 10 days ago

NV-387 Shows Promise Against Measles, Protects Lungs

NV-387 Clinical Trials Antiviral Lung Protection Measles
PRESS RELEASE

published on 10/22/2025 at 14:45, 6 months 10 days ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action

NanoViricides NV-387 Clinical Trial Antiviral Drug Measles Virus
BRIEF

published on 10/20/2025 at 14:50, 6 months 12 days ago

NanoViricides Announces Promising Measles Treatment

NanoViricides NV-387 Antiviral Drug Measles Treatment Emergency Use
PRESS RELEASE

published on 10/20/2025 at 14:45, 6 months 12 days ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
NanoViricides, Inc. announces NV-387, a drug showing strong activity against Measles virus in an animal model, available for emergency use. Drug has completed Phase I clinical trial

NanoViricides NV-387 Emergency Use Measles Virus Phase I

Published on 05/01/2026 at 15:35, 42 minutes ago

LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 14:00, 2 hours 17 minutes ago

CCL Industries Closing of ALT Technologies Acquisition
Published on 05/01/2026 at 14:00, 2 hours 17 minutes ago

Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions
Published on 05/01/2026 at 13:01, 3 hours 16 minutes ago

BeMetals Announces Resumption of Trading on TSX Venture Exchange and Effective Date of Share Consolidation
Published on 05/01/2026 at 13:00, 3 hours 17 minutes ago

Abasca Resources to Participate in Core Days 2026 and Closes $2.5 Million Private Placement

View all ACCESSWIRE

Published on 05/01/2026 at 15:59, 17 minutes ago

Shares Admitted to Trading and Total Voting Rights
Published on 05/01/2026 at 15:37, 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 05/01/2026 at 15:36, 41 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 05/01/2026 at 15:35, 42 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 05/01/2026 at 15:34, 43 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc

View all EQS

Published on 04/30/2026 at 20:00, 20 hours 16 minutes ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 21 hours 1 minute ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 21 hours 17 minutes ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 22 hours 7 minutes ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 22 hours 17 minutes ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News